77 related articles for article (PubMed ID: 32629391)
41. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
[TBL] [Abstract][Full Text] [Related]
42. Overview of current systemic management of EGFR-mutant NSCLC.
Hsu WH; Yang JC; Mok TS; Loong HH
Ann Oncol; 2018 Jan; 29(suppl_1):i3-i9. PubMed ID: 29462253
[TBL] [Abstract][Full Text] [Related]
43. Evaluation of plasma EGFR mutation as an early predictor of response of erlotinib plus bevacizumab treatment in the NEJ026 study.
Fukuhara T; Saito H; Furuya N; Watanabe K; Sugawara S; Iwasawa S; Tsunezuka Y; Yamaguchi O; Okada PM; Yoshimori K; Nakachi I; Gemma PA; Azuma K; Kurimoto F; Tsubata Y; Fujita Y; Nagashima H; Asai G; Watanabe S; Miyazaki M; Hagiwara PK; Nukiwa PT; Morita PS; Kobayashi PK; Maemondo PM
EBioMedicine; 2020 Jul; 57():102861. PubMed ID: 32629391
[TBL] [Abstract][Full Text] [Related]
44. Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation sequencing results.
Garon EB; Reck M; Nishio K; Heymach JV; Nishio M; Novello S; Paz-Ares L; Popat S; Aix SP; Graham H; Butts BD; Visseren-Grul C; Nakagawa K;
ESMO Open; 2023 Aug; 8(4):101580. PubMed ID: 37390764
[TBL] [Abstract][Full Text] [Related]
45. Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial.
Rosell R; Dafni U; Felip E; Curioni-Fontecedro A; Gautschi O; Peters S; Massutí B; Palmero R; Aix SP; Carcereny E; Früh M; Pless M; Popat S; Kotsakis A; Cuffe S; Bidoli P; Favaretto A; Froesch P; Reguart N; Puente J; Coate L; Barlesi F; Rauch D; Thomas M; Camps C; Gómez-Codina J; Majem M; Porta R; Shah R; Hanrahan E; Kammler R; Ruepp B; Rabaglio M; Kassapian M; Karachaliou N; Tam R; Shames DS; Molina-Vila MA; Stahel RA;
Lancet Respir Med; 2017 May; 5(5):435-444. PubMed ID: 28408243
[TBL] [Abstract][Full Text] [Related]
46. EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.
Otsuka K; Hata A; Takeshita J; Okuda C; Kaji R; Masago K; Fujita S; Katakami N
Cancer Chemother Pharmacol; 2015 Oct; 76(4):835-41. PubMed ID: 26349474
[TBL] [Abstract][Full Text] [Related]
47. Investigation of efficacy and acquired resistance for EGFR-TKI plus bevacizumab as first-line treatment in patients with EGFR sensitive mutant non-small cell lung cancer in a Real world population.
Zeng L; Xiao L; Jiang W; Yang H; Hu D; Xia C; Li Y; Zhou C; Xiong Y; Liu L; Liao D; Guan R; Li K; Wang J; Zhang Y; Yang N; Mansfield AS
Lung Cancer; 2020 Mar; 141():82-88. PubMed ID: 31982639
[TBL] [Abstract][Full Text] [Related]
48. Circulating Tumor DNA Analysis for Patients with Oncogene-Addicted NSCLC With Isolated Central Nervous System Progression.
Aldea M; Hendriks L; Mezquita L; Jovelet C; Planchard D; Auclin E; Remon J; Howarth K; Benitez JC; Gazzah A; Lavaud P; Naltet C; Lacroix L; de Kievit F; Morris C; Green E; Ngo-Camus M; Rouleau E; Massard C; Caramella C; Friboulet L; Besse B
J Thorac Oncol; 2020 Mar; 15(3):383-391. PubMed ID: 31843682
[TBL] [Abstract][Full Text] [Related]
49. Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial.
Molina-Vila MA; Stahel RA; Dafni U; Jordana-Ariza N; Balada-Bel A; Garzón-Ibáñez M; García-Peláez B; Mayo-de-Las-Casas C; Felip E; Curioni Fontecedro A; Gautschi O; Peters S; Massutí B; Palmero R; Ponce Aix S; Carcereny E; Früh M; Pless M; Popat S; Cuffe S; Bidoli P; Kammler R; Roschitzki-Voser H; Tsourti Z; Karachaliou N; Rosell R
J Thorac Oncol; 2020 Mar; 15(3):416-425. PubMed ID: 31812754
[TBL] [Abstract][Full Text] [Related]
50. Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study.
Hosomi Y; Morita S; Sugawara S; Kato T; Fukuhara T; Gemma A; Takahashi K; Fujita Y; Harada T; Minato K; Takamura K; Hagiwara K; Kobayashi K; Nukiwa T; Inoue A;
J Clin Oncol; 2020 Jan; 38(2):115-123. PubMed ID: 31682542
[TBL] [Abstract][Full Text] [Related]
51. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.
Nakagawa K; Garon EB; Seto T; Nishio M; Ponce Aix S; Paz-Ares L; Chiu CH; Park K; Novello S; Nadal E; Imamura F; Yoh K; Shih JY; Au KH; Moro-Sibilot D; Enatsu S; Zimmermann A; Frimodt-Moller B; Visseren-Grul C; Reck M;
Lancet Oncol; 2019 Dec; 20(12):1655-1669. PubMed ID: 31591063
[TBL] [Abstract][Full Text] [Related]
52. Longitudinal monitoring of somatic genetic alterations in circulating cell-free DNA during treatment with epidermal growth factor receptor-tyrosine kinase inhibitors.
Iwama E; Sakai K; Hidaka N; Inoue K; Fujii A; Nakagaki N; Ota K; Toyozawa R; Azuma K; Nakatomi K; Harada T; Hisasue J; Sakata S; Shimose T; Kishimoto J; Nakanishi Y; Nishio K; Okamoto I
Cancer; 2020 Jan; 126(1):219-227. PubMed ID: 31503343
[TBL] [Abstract][Full Text] [Related]
53. Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer.
Gray JE; Okamoto I; Sriuranpong V; Vansteenkiste J; Imamura F; Lee JS; Pang YK; Cobo M; Kasahara K; Cheng Y; Nogami N; Cho EK; Su WC; Zhang G; Huang X; Li-Sucholeiki X; Lentrichia B; Dearden S; Jenkins S; Saggese M; Rukazenkov Y; Ramalingam SS
Clin Cancer Res; 2019 Nov; 25(22):6644-6652. PubMed ID: 31439584
[TBL] [Abstract][Full Text] [Related]
54. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial.
Saito H; Fukuhara T; Furuya N; Watanabe K; Sugawara S; Iwasawa S; Tsunezuka Y; Yamaguchi O; Okada M; Yoshimori K; Nakachi I; Gemma A; Azuma K; Kurimoto F; Tsubata Y; Fujita Y; Nagashima H; Asai G; Watanabe S; Miyazaki M; Hagiwara K; Nukiwa T; Morita S; Kobayashi K; Maemondo M
Lancet Oncol; 2019 May; 20(5):625-635. PubMed ID: 30975627
[TBL] [Abstract][Full Text] [Related]
55. Clinical utility of a blood-based EGFR mutation test in patients receiving first-line erlotinib therapy in the ENSURE, FASTACT-2, and ASPIRATION studies.
Wu YL; Lee V; Liam CK; Lu S; Park K; Srimuninnimit V; Wang J; Zhou C; Appius A; Button P; Hooper G; Palma JF; Schulze K; Scudder S; Shames DS; Yin AY; Zhang G; Mok T;
Lung Cancer; 2018 Dec; 126():1-8. PubMed ID: 30527172
[TBL] [Abstract][Full Text] [Related]
56. Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial.
Wang Z; Cheng Y; An T; Gao H; Wang K; Zhou Q; Hu Y; Song Y; Ding C; Peng F; Liang L; Hu Y; Huang C; Zhou C; Shi Y; Zhang L; Ye X; Zhang M; Chuai S; Zhu G; Hu J; Wu YL; Wang J
Lancet Respir Med; 2018 Sep; 6(9):681-690. PubMed ID: 30017884
[TBL] [Abstract][Full Text] [Related]
57. Monitoring of somatic mutations in circulating cell-free DNA by digital PCR and next-generation sequencing during afatinib treatment in patients with lung adenocarcinoma positive for EGFR activating mutations.
Iwama E; Sakai K; Azuma K; Harada T; Harada D; Nosaki K; Hotta K; Ohyanagi F; Kurata T; Fukuhara T; Akamatsu H; Goto K; Shimose T; Kishimoto J; Nakanishi Y; Nishio K; Okamoto I
Ann Oncol; 2017 Jan; 28(1):136-141. PubMed ID: 28177428
[TBL] [Abstract][Full Text] [Related]
58.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
